We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
- Authors
Kim, Sung-Ho; Lee, Sung-Hack; Yim, Hyeon-Joo
- Abstract
Gemigliptin, a potent, selective and long-acting DPP 4 inhibitor was developed by LG Life Sciences and approved for use in patients with type 2 diabetes mellitus by the Korean Food and Drug Administration in June 2012 under the trade name Zemiglo. Clinical pharmacokinetic and pharmacodynamic data suggest the efficacy and once daily dosing of gemigliptin. In clinical phase III studies, gemigliptin was efficacious as either monotherapy or combination therapy (add-on to metformin) and well tolerated in patients with type 2 diabetes. Further development of combination therapy is on-going.
- Publication
Archives of Pharmacal Research, 2013, Vol 36, Issue 10, p1185
- ISSN
0253-6269
- Publication type
Report
- DOI
10.1007/s12272-013-0171-x